92241-87-7

Upstream product

• 67579-92-4 3-methoxy-4-nitrobenzoic acid chloride 
• 185629-31-6 methyl 3-fluoro-4-nitrobenzoate 
• 5081-37-8 methyl 3-methoxy-4-nitrobenzoate 
• 403-21-4 3-fluoro-4-nitrobenzoic acid 
• 5081-36-7 3-methoxy-4-nitrobenzoic acid 

Downstream Products

• 149555-78-2 3-methoxy-4-nitrobenzylamine 
• 211374-82-2 4-amino-3-methoxybenzamide 
• 53484-14-3 3-methyl-3H-benzoimidazole-5-carbonitrile 
• 6595-25-1 1.2-Dimethyl-6-benzimidazol-carbonitril 
• 864274-50-0 3-[(2-cyclohexylethyl)amino]-4-nitrobenzonitrile 
• 864273-80-3 3-{[2-(4-morpholinyl)ethyl]amino}-4-nitrobenzonitrile 
• 864274-39-5 3-[(3,3-dimethylbutyl)amino]-4-nitrobenzonitrile 
• 864274-87-3 3-[(2-cyclopropylethyl)amino]-4-nitrobenzonitrile 
• 864275-07-0 4-amino-3-(cyclopropylmethylamino)benzonitrile 
• 864274-02-2 1-methyl-1H-1,2,3-benzotriazole-6-carbonitrile 
• 181867-19-6 1-methyl-1H-benzo[d]imidazole-6-carbaldehyde 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS STING MODULATORS

Disclosed herein are heterocyclic compounds that may be used as STING modulators, process for synthesis and to uses of such compounds in treatment of various diseases including cancers.

STING AGONIST COMPOUNDS AND METHODS OF USE

The present disclosure relates to STING (Stimulator of Interferon Genes) agonist compounds, methods of making the compounds and their methods of use.

TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists

There are provided compounds of the general formula wherein A, B, V, W, R1, R2, R3, R3, and R4, are as described herein and enantiomers and pharmaceutically acceptable salts thereof. The compounds are useful as anticancer agents.

PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

SPIROINDOLINONE PYRROLIDINES

There are provided compounds of the formula wherein X, Y and R1 to R8 are described herein along with the enantiomers, pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.

SPIROINDOLINONE PYRROLIDINES

There are provided compounds of the formula (I) wherein X, Y and R1 to R8 are as described herein, their enantiomers and pharmaceutically acceptable salts and esters, as well as processes for making these compounds and medicaments containing them.

Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ

3-Methoxybenzamide is a weak inhibitor of the essential bacterial cell division protein FtsZ. Exploration of the structure-activity relationships of 3-methoxybenzamide analogues led to the identification of potent anti-staphylococcal compounds.